Reply to Brief in Opposition by Ravicher, Daniel B. et al.
No. 11-725
IN THE
Supreme Court of the United States
THE ASSOCIATION FOR MOLECULAR PATHOLOGY, ET AL.,
Petitioners,
—v.—
MYRIAD GENETICS, INC., ET AL.,
Respondents.
ON PETITION FOR A WRIT OF CERTIORARI TO THE UNITED STATES 
COURT OF APPEALS FOR THE FEDERAL CIRCUIT


















Benjamin N. Cardozo 
School of Law
55 Fifth Avenue, Suite 928
New York, NY 10003
 i 
 
TABLE OF AUTHORITIES 
CASES 
MedImmune, Inc. v. Genentech, Inc.,                                       
549 U.S. 118 (2007) ................................................. 4 
OTHER AUTHORITIES 
M. Garber et al., “Closing Gaps in the Human 
Genome Using Sequencing by Synthesis,”             
Genome Biol. 2009; 10(6) R60 EPub 2009 Jun 2. 
http://www.ncbi.nlm.nih.gov/pubmed/19490611 .... 5 
Myriad Genetics Acquires Exclusive Rights to 
RAD51C Gene, Myriad Genetics,                          
(January 18, 2012), 
http://investor.myriad.com/releasedetail.cfm?Relea




THIS CASE IS AN APPROPRIATE AND 
IMPORTANT VEHICLE FOR ADDRESSING 
THE FEDERAL CIRCUIT’S ERROR IN 
CONCLUDING THAT HUMAN GENES ARE 
PATENTABLE AND THAT STANDING 
DOCTRINE IN PATENT CASES IS UNIQUE. 
 In their Brief in Opposition, Respondents 
Myriad Genetics et al. (Myriad) offer a flurry of 
arguments to suggest that the Court should deny the 
Petition.  Not only do none of those arguments have 
merit, many are implicitly contradicted by positions 
taken by Myriad and its amici in the lower courts. 
 Myriad argues that this Court will be 
embroiled in a cumbersome argument concerning the 
standing of petitioner Harry Ostrer, the plaintiff that 
the Federal Circuit found to have standing.   BIO at 
27-28.  Respondents note that Dr. Ostrer recently 
moved from one hospital where he directed genetic 
research and clinical practice (NYU) to another 
hospital where he continues to direct genetic 
research and clinical practice (Montefiore).  
Respondents do not mention that they raised this 
issue in a Motion for Panel Rehearing in the Federal 
Circuit.  The Circuit requested petitioners respond.  
Petitioners responded with a declaration by Dr. 
Ostrer that said, in part: 
4.  At the Human Genetics Program and 
Molecular Genetics Laboratory at NYU, 
“that I direct[ed], my staff and I 
engage[d] in both research and clinical 
practice relating to genetic related 
susceptibility to disease.”  A 1464.  As 
Director of Genetics and Genomic 
Diagnostics at Montefiore Medical 
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Center, which I direct, my staff and I 
engage in both research and clinical 
practice relating to genetically related 
susceptibility to disease. 
5.  At NYU, “I ha[d] the capability and 
desire” to “provide patients with the 
results of BRCA1/2 related genetic 
screening for the susceptibility to breast 
cancer.  A 1464.  I have the same 
capability and desire at Montefiore. … 
8.  At NYU, I had “all of the personnel, 
expertise, and facilities necessary to do 
various types of sequencing of the 
BRCA1 and BRCA2 genes and I [had] 
the strong desire for my lab to provide 
such sequencing services.”  A 1466.  At 
Montefiore, I have all of the personnel, 
expertise and facilities necessary to do 
various types of sequencing of the 
BRCA1 and BRCA2 genes and I have 
the strong desire for my lab to provide 
such sequencing services. 
Suppl. Decl. of Harry Ostrer, dated Sept. 12, 2011, 
attach. to Pls.’-Appellees’ Answer to Defs.’-
Appellants’ Pet. for Panel Reh’g, Sept. 14, 2011, Ass’n 
for Molecular Pathology v. U.S.P.T.O., 653 F.3d 1329 
(Fed. Cir. 2011)(No. 2010-1406).  Myriad argues that 
Dr. Ostrer nevertheless does not have standing 
because the letter threatening him for infringing 
Myriad’s patents was sent to him at an NYU 
address, not at a Montefiore address.  Dr. Ostrer’s 
declaration also addressed this argument. 
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12.  I am aware that Myriad has argued 
that the letter I received should be 
considered as directed solely at NYU 
and its employees and not at me.  I 
cannot reconcile that argument with the 
fact that the letter was addressed to me 
by name.  It is inconceivable to me that 
I could have moved to a different job, 
engaged in the exact same activity, and 
been certain that Myriad would take no 
action.  I felt personally threatened then 
and I continue to feel so today. 
Id.  As a result of that declaration, the Federal 
Circuit denied Myriad’s Motion for Panel Rehearing.  
Order, September 16, 2011.  That Myriad continues 
to advance that argument in this Court highlights 
the narrow standing rules applied by the Federal 
Circuit, which are inconsistent with this Court’s 
holding in MedImmune, Inc. v. Genentech, Inc., 549 
U.S. 118 (2007), and which led the Federal Circuit to 
improperly deny standing to the other plaintiffs in 
this case.   See Pet. at 31-35.   If anything, therefore, 
Myriad’s standing argument simply reinforces the 
need for this Court to grant Question 2 presented by 
the Petition. 
 Myriad also raises a series of arguments 
suggesting that this case represents an inappropriate 
vehicle to decide the Questions Presented.  Those 
arguments are equally without merit.  In some cases, 
Myriad does not mention that its argument was 
raised and rejected by the Federal Circuit.1  In other 
                                                 
1 Compare BIO at 29 (plaintiffs cannot obtain meaningful relief 
because they challenged only some of Myriad’s patent claims), 
with Pet.App. at 37-8 (plaintiffs can obtain meaningful relief 
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instances, Myriad does not mention the extensive 
evidence contradicting its assertions.2  And in some 
instances, Myriad makes arguments that are 
unsupported by the record and that are simply 
wrong.3 
 Underlying all of these and similar arguments 
made by Myriad is the implicit assertion that the 
issues in this case are not very important.  That 
                                                                                                    
and “Myriad has failed to direct us to any specific unchallenged 
claim that will” prevent meaningful relief). 
2 Compare BIO at 30 (research papers have been published on 
BRCA1/2), with Pet.App. at 170a-178a and Fed.Cir.App. at 
A7271(Myriad’s patents have impeded research; the number of 
papers published is misleading because it simply lists papers in 
which the genes have been mentioned.)  See also Brief of 
American Medical Association et al. as Amici Curiae in Support 
of Petitioners, Jan. 10, 2012 at 14-15; Amici Brief of the 
National Women’s Health Network, et al. in Support of Petition 
for Writ of Certiorari, Jan. 11, 2012, at 8-10; Brief of Amicus 
Curiae Information Society Project at Yale Law School Scholars 
in Support of the Petition, Jan. 13, 2012 at 9-20. 
3 Compare BIO at 25 (publication of the human genome 
sequence renders the case unimportant for the future) with Pet. 
App. at 126-29 and e.g. Amici Brief of the National Women’s 
Health Network et al. in Support of Petition for Writ of 
Certiorari, Jan. 11, 2012 at 6-20  (women are being and will 
continue to be harmed).  See also M. Garber et al., “Closing 
Gaps in the Human Genome Using Sequencing by Synthesis,” 
Genome Biol. 2009; 10(6) R60 EPub 2009 Jun 2. 
http://www.ncbi.nlm.nih.gov/pubmed/19490611 (gaps in genome 
identification remain)(viewed January 19, 2012).  It also ignores 
that patents on genes are still being sought and granted.  See 
e.g. U.S. Patent 7,928,212 (issued April 19, 2011).  Finally, it 
ignores Myriad’s own statements that gene patents remain 
enormously important.  E.g. Myriad Genetics Acquires Exclusive 
Rights to RAD51C Gene, Myriad Genetics (January 18, 2012), 
http://investor.myriad.com/releasedetail.cfm?ReleaseID=640654 
(Myriad press release bragging about purchase of new gene 
patents)(viewed January 19, 2012) 
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argument is strikingly contradicted by numerous 
assertions made by Myriad and its amici in the lower 
courts.  See e.g. Second Corrected App. at A3440, 
Ass’n for Molecular Pathology v. U.S.P.T.O., 653 F.3d 
1329 (Fed. Cir. 2011)(No. 2010-1406)(Fed. Cir. App.) 
(Myriad Defendants’ District Court Memorandum of 
Law) (a ruling for plaintiffs “would…effectively 
unravel the foundation of the entire biotechnology 
industry…”); Id. at A3467 (a ruling for plaintiffs 
would be “disastrous for an entire industry”); Brief 
for Appellants at 3-4, Ass’n for Molecular Pathology, 
supra, Oct. 22, 2010 (“If this judgment is not 
reversed… valuable future developments [in 
“identifying and curing genetic disorders and other 
diseases”] will slow or cease…”).  The vast number of 
amicus curiae briefs that Myriad assembled in the 
Federal Circuit attest to Myriad’s view of the 
importance of this case.4  Pet. App. at 3a-7a. 
 In short, it is simply too late for Myriad to now 
argue that this case is unimportant.  This Court 
should grant the petition to address the issues that 
(until now) both parties agree are of enormous 
importance. 
  
                                                 
4 See e.g. Brief of Amicus Curiae Boston Patent Law Association 
in Support of Defendants-Appellants and Reversal of Summary 
Judgment, Oct. 29, 2010 at 1, Ass’n for Molecular Pathology, 
supra, Oct. 22, 2010, (if plaintiffs prevail, it will “hinder the 
development of better diagnostics and therapies, cripple the 
biotechnology industry, and discourage innovation generally”); 
id.at 19 (“The BPLA views this case not just as a narrow 
question of whether certain isolated DNA claims are patentable 




 For the reasons stated above and in the 
petition, a writ of certiorari should be granted to 
review the judgment of the Federal Circuit in this 
case. 
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